Page 3 - Renal Dysfunction News Today

Bristol Myers Squibb Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders First Phase 3 data from the RELATIVITY-047 trial highlight clinical benefit of LAG-3 blocking antibody relatlimab the company’s third distinct checkpoint inhibitor in combination with nivolumab for patients with previously untreated unresectable or metastatic melanoma First disclosure of results from CheckMate -648 ...

Recommendation based on positive results from the Phase 3 CheckMate -743 trial, in which Opdivo plus Yervoy demonstrated significantly superior overall survival vs. standard-of-care chemotherapy CheckMate -743 represents the first Phase 3 trial to show benefit with immunotherapy in previously untreated malignant pleural mesothelioma If approved, Opdivo plus Yervoy will be the first new treatment option authorized … Recommendation based on positive results from the Phase 3 CheckMate -743 tria...

Two Opdivo -based therapies are now authorized for first-line treatment of patients with advanced renal cell carcinoma in the European Union: Opdivo plus Yervoy in combination with Cabometyx Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo Cabometyx ® (cabozantinib) for the first-line treatment of adults with advanced renal cell carcinoma (RCC). The EC’s decision is based on results from the Phase 3 CheckMate -9ER tri...

Nearly a quarter of patients who received Opdivo plus chemotherapy showed no evidence of cancer cells in tissue removed during surgery vs. 2.2% of patients who received chemotherapy alone Opdivo- based therapies have now demonstrated positive results in Phase 3 trials in earlier stages of four different types of cancer: non-small cell lung cancer, esophagealgastroesophageal junction cancer, bladder cancer and … Nearly a quarter of patients who received Opdivo plus chemotherapy showed no e...

1 1,2 as a standard of care for intermediate- or poor-risk patients 3 OPDIVO ® (nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks in combination with CABOMETYX ® (cabozantinib) 40 mg once daily tablets was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). 1 The approval is based on the Phase 3 CheckMate -9ER trial, which compared OPDIVO in co...

Bristol Myers Squibb Announces Update on Phase 3 CheckMate -548 Trial Evaluating Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme Bristol Myers Squibb today announced an update on CheckMate -548, a Phase 3 trial evaluating the addition of Opdivo to the current standard of care versus placebo plus the standard of care in patients with newly diagnosed glioblastoma multiforme with O6-methylguanine-DNA methyltransferase promoter methylation following surgical resection of the t...